Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due consideration to any comments thereon received from the Investors or their counsel.
Appears in 12 contracts
Samples: Registration Rights Agreement (Tectonic Therapeutic, Inc.), Registration Rights Agreement (Immunovant, Inc.), Registration Rights Agreement (AtlasClear Holdings, Inc.)
Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due consideration to any comments thereon received from the Investors or their counsel.
Appears in 3 contracts
Samples: Registration Rights Agreement (Tenax Therapeutics, Inc.), Registration Rights Agreement (Grace Therapeutics, Inc.), Registration Rights Agreement (Tenax Therapeutics, Inc.)
Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three four (34) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due consideration to any comments thereon received from the Investors or their counsel.
Appears in 3 contracts
Samples: Registration Rights Agreement (Biodesix Inc), Registration Rights Agreement (Pyxis Oncology, Inc.), Registration Rights Agreement (IO Biotech, Inc.)
Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due good faith consideration to any comments thereon received from the Investors or their counsel.
Appears in 2 contracts
Samples: Registration Rights Agreement (Cidara Therapeutics, Inc.), Registration Rights Agreement (Oruka Therapeutics, Inc.)
Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby hereby, unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due consideration to any comments thereon received from the Investors or their counsel.
Appears in 2 contracts
Samples: Registration Rights Agreement (Aligos Therapeutics, Inc.), Registration Rights Agreement (Aligos Therapeutics, Inc.)
Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three one (31) Business Days Day prior to filing with the SEC and (B) the Company shall have given reasonable due consideration to any comments thereon received from the Investors or their counsel.
Appears in 2 contracts
Samples: Registration Rights Agreement (Summit Therapeutics Inc.), Registration Rights Agreement (Summit Therapeutics Inc.)
Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investorsany Investor, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors Investor and their its counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due good faith consideration to any comments thereon received from the Investors Investor or their its counsel.
Appears in 2 contracts
Samples: Registration Rights Agreement (Aerovate Therapeutics, Inc.), Securities Purchase Agreement (Aerovate Therapeutics, Inc.)
Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable good faith and due consideration to any comments thereon received from the Investors or their counsel.
Appears in 1 contract
Samples: Registration Rights Agreement (RAPT Therapeutics, Inc.)
Investor Review. The Company will not file any amendment or supplement to the Initial Registration Statement, Warrant Initial Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due consideration to any comments thereon received from the Investors or their counsel.
Appears in 1 contract
Samples: Registration Rights Agreement (Inhibikase Therapeutics, Inc.)
Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement, any Special Registration Statement or any prospectus, other than documents incorporated by reference, relating to the InvestorsInvestor, the Registrable Securities or the transactions contemplated hereby unless (Ai) the Investors Investor and their its counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (Bii) the Company shall have given reasonable good faith and due consideration to any comments thereon received from the Investors Investor or their its counsel.
Appears in 1 contract
Investor Review. The Company will not file any amendment or supplement to the Initial Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days business days prior to filing with the SEC and (B) the Company shall have given reasonable due consideration to any comments thereon received from the Investors or their counsel.
Appears in 1 contract
Samples: Registration Rights Agreement (Outset Medical, Inc.)
Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investorsany Investor, the Registrable Securities or the transactions β β contemplated hereby unless (A) the Investors such Investor and their its counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due consideration to any comments thereon received from the Investors such Investor or their its counsel.
Appears in 1 contract